Edition:
United States

Syndax Pharmaceuticals Inc (SNDX.OQ)

SNDX.OQ on NASDAQ Stock Exchange Global Select Market

7.27USD
18 Jul 2018
Change (% chg)

-- (--)
Prev Close
$7.27
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
98,064
52-wk High
$15.20
52-wk Low
$6.65

Latest Key Developments (Source: Significant Developments)

Syndax And Nektar Therapeutics Announce Immuno-Oncology Clinical Trial Collaboration
Wednesday, 30 May 2018 04:05pm EDT 

May 30 (Reuters) - Nektar Therapeutics ::SYNDAX AND NEKTAR THERAPEUTICS ANNOUNCE IMMUNO-ONCOLOGY CLINICAL TRIAL COLLABORATION.NEKTAR- ANNOUNCED NON-EXCLUSIVE, CLINICAL COLLABORATION TO EVALUATE SAFETY, EFFICACY OF NEKTAR'S NKTR-214, IN COMBINATION WITH SYNDAX'S ENTINOSTAT.NEKTAR THERAPEUTICS - COLLABORATION WILL EVALUATE COMBINATION OF ENTINOSTAT WITH NKTR-214 IN PATIENTS WITH PD-1 REFRACTORY MELANOMA.NEKTAR THERAPEUTICS - ADDITIONAL FINANCIAL DETAILS AND OTHER TERMS OF AGREEMENT WERE NOT DISCLOSED.  Full Article

Syndax Pharmaceuticals Announces Clinical Collaboration To Evaluate Entinostat In Combination With Anti-Pd-L1 Cancer Immunotherapy In Breast Cancer
Wednesday, 10 Jan 2018 07:00am EST 

Jan 10 (Reuters) - Syndax Pharmaceuticals Inc ::SYNDAX PHARMACEUTICALS ANNOUNCES CLINICAL COLLABORATION TO EVALUATE ENTINOSTAT IN COMBINATION WITH ANTI-PD-L1 CANCER IMMUNOTHERAPY IN BREAST CANCER.SYNDAX PHARMACEUTICALS INC - NEW CLINICAL COLLABORATION WITH GENENTECH, A MEMBER OF ROCHE GROUP.SYNDAX PHARMACEUTICALS - COS WILL EVALUATE COMBINATION OF CO'S ENTINOSTAT AND GENENTECH'S ATEZOLIZUMAB.SYNDAX PHARMACEUTICALS INC - FINANCIAL AND OTHER TERMS OF AGREEMENT WERE NOT DISCLOSED..SYNDAX PHARMACEUTICALS INC - GENENTECH WILL BE RESPONSIBLE FOR CONDUCTING TRIAL.SYNDAX PHARMACEUTICALS INC - TRIAL WILL BE CONDUCTED AS PART OF MORPHEUS, ROCHE'S NOVEL CANCER IMMUNOTHERAPY DEVELOPMENT PLATFORM.  Full Article

Syndax Pharmaceuticals reports Q3 loss per share $0.68
Tuesday, 7 Nov 2017 04:05pm EST 

Nov 7 (Reuters) - Syndax Pharmaceuticals Inc ::Syndax pharmaceuticals reports third quarter 2017 financial results and provides clinical and business update.Q3 loss per share $0.68.Q3 earnings per share view $-0.80 -- Thomson Reuters I/B/E/S.  Full Article

Syndax Pharma enters into license agreement with unit of Allergan
Tuesday, 17 Oct 2017 07:53am EDT 

Oct 17 (Reuters) - Syndax Pharmaceuticals :On Oct 13, co entered into license agreement with Vitae Pharmaceuticals, a subsidiary of Allergan Plc​ - SEC filing.Pursuant to agreement, co will make an upfront payment of $5.0 million to Allergan​.If parties commercialize Menin assets, co obligated to pay Allergan low single to low double-digit royalties on sales​.Under agreement, Allergan grants co worldwide license to portfolio of orally-available small molecule inhibitors of interaction of MLL protein​.Under agreement, may have to pay allergan up to $99 million in one-time development, regulatory milestone payments subject to achievement of milestones.In event of commercializing Menin assets, co to also pay up to $70 million in potential one-time sales-based milestone payments​.Company will be solely responsible for development and commercialization of Menin assets​.Under certain circumstances, co may be required to share a percentage of non-royalty income from sublicensees, with Allergan​.  Full Article

Syndax Pharmaceuticals says ‍expands pipeline with exclusive worldwide license to Allergan's portfolio of Menin-MLL inhibitors​
Tuesday, 17 Oct 2017 07:00am EDT 

Oct 17 (Reuters) - Syndax Pharmaceuticals Inc ::Syndax Pharmaceuticals Inc - ‍expands pipeline with exclusive worldwide license to Allergan's portfolio of Menin-MLL inhibitors​.Syndax Pharmaceuticals Inc - ‍ entered into an exclusive worldwide license agreement with Vitae Pharmaceuticals, inc., a subsidiary of Allergan PLC​.  Full Article

Syndax Pharmaceuticals Q2 loss per share $0.47
Tuesday, 9 Aug 2016 06:30am EDT 

Syndax Pharmaceuticals Inc : Syndax Pharmaceuticals reports second quarter 2016 financial results and provides business update . Q2 earnings per share view $-0.54 -- Thomson Reuters I/B/E/S . Q2 loss per share $0.47 .Progressing to phase 2 of ENCORE 601 in NSCLC and Melanoma.  Full Article

BRIEF-Syndax Announces Updated Results From Phase 2 Encore 601 Trial Of Entinostat In Combination With Keytruda®

* SYNDAX ANNOUNCES UPDATED RESULTS FROM PHASE 2 ENCORE 601 TRIAL OF ENTINOSTAT IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB)